AstraZeneca Hits And Misses: Trio Of EU Label Expansions But US Lynparza Review Delayed
Executive Summary
The major has won two positive CHMP opinions and one EU approval for meaningful label expansions across its oncology and cardiology franchises, but a delayed US review for prostate cancer drug Lynparza has put a spanner in the works.
You may also be interested in...
Enhertu Goes Into High Gear With HER2-Low Breast Cancer Approval
AstraZeneca and partner Daiichi Sankyo obtain the first approval for targeted therapy in HER2-low metastatic breast cancer for Enhertu, about four months ahead of the FDA action date.
AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data
AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.
Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.